Abstract: It is an object of the present invention to apply a novel method of preparing neural cells from ES cells. The method of the present invention is characterized by the electric pulse treatment of differentiating ES cells. Nerve cells obtained by the method of the present invention have the flexibility to differentiate into a variety of types of neurons in vivo preferably without the need for application of growth factors.
Abstract: The present invention relates to compositions and methods for the protection and restoration of hearing. In particular, the present invention relates to treatments to facilitate the protection and re-growth of the auditory nerve. The present invention further provides methods of preventing hair cell loss and the accompanying loss in hearing. The present invention thus provides novel interventions for a variety of hearing impairments.
Type:
Grant
Filed:
January 16, 2003
Date of Patent:
April 20, 2010
Assignee:
The Regents of the University of Michigan
Inventors:
Josef M. Miller, Richard A. Altschuler, Yehoash Raphael
Abstract: A method of diagnosing Alzheimer's disease in a patient comprises determining whether the phosphorylation level of an indicator protein in cells of the patient after stimulus with an activator compound is abnormally elevated as compared to a basal phosphorylation level, the indicator protein being e.g. Erk1/2 and the activator compound being e.g. bradykinin.
Type:
Grant
Filed:
February 27, 2002
Date of Patent:
March 23, 2010
Assignee:
Blanchette Rockefeller Neurosciences Institute
Abstract: Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.
Type:
Grant
Filed:
June 6, 2007
Date of Patent:
March 23, 2010
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Paolo Francesco Fabene, Eugene C. Butcher, Gabriela Constantin
Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
Type:
Grant
Filed:
August 25, 2006
Date of Patent:
March 16, 2010
Assignee:
BrainCells Inc
Inventors:
Carrolee Barlow, Todd A. Carter, Kym I. Lorrain, Jammieson C. Pires, Andrew Morse, Dana Gitnick, Kai Treuner, Alex Broadhead
Abstract: Compositions containing aequorin and methods for their use in preventing and/or alleviating symptoms and disorders related to calcium imbalance are provided by the present invention.
Abstract: The object of the present invention is to provide methods for inhibiting proliferation of neural stem cells, an agent for inhibiting proliferation of neural stem cells, and methods for using the same. According to the method of the present invention, a galectin-1 inhibitor such as anti-galectin-1 antibody and/or an integrin ?1 inhibitor such as anti-integrin ?1 antibody is administered to a human or a vertebrate other than human for inhibiting proliferation of neural stem cells. This method can be used for treatment of nerve injury and nerve tumors.
Type:
Grant
Filed:
February 9, 2007
Date of Patent:
February 16, 2010
Assignees:
Keio University, Advanced Industrial Science and Technology
Inventors:
Hideyuki Okano, Kazunobu Sawamoto, Masanori Sakaguchi, Jun Hirabayashi
Abstract: The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.
Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
Abstract: This invention provides platelet-derived growth factor-responsive neural precursor (PRP) cells and methods of producing such cells in vivo or in vitro. These cells can further be used to generate neurons, oligodendrocytes and/or astrocytes.
Abstract: The present invention provides a novel drug/agent for the prevention and/or treatment of Alzheimer's disease based on a different Alzheimer's disease onset mechanism from the amyloid hypothesis, and a method of screening for it.
Abstract: SVCT2 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the SVCT2 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in screening for therapeutic, cytotoxic or imaging compounds used in the treatment or diagnosis of neurological diseases.
Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
Abstract: A biological nerve guide for implantation into a human body is made by providing a natural animal tissue membrane, crosslinking and fixing the membrane, minimizing the antigens from the membrane, tanning the membrane, coupling an active layer to an inner surface of the membrane, cutting the membrane into a desired shape and size, positioning the cut membrane onto a rod-shaped mold so that the cut membrane assumes a cylindrical configuration, and attaching a spiral support to the outer surface of the cut membrane.
Abstract: Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1? (HIF-1?). HIF-1? is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized.
Type:
Grant
Filed:
August 10, 2005
Date of Patent:
November 17, 2009
Assignee:
HealthPartners Research Foundation
Inventors:
William H. Frey, II, Samual Scott Panter, Leah Ranae Bresin Hanson
Abstract: Traumatic insult to the brain leads to a degradation of low molecular weight of cannabinoid type 1 receptor (CB1) and generation of high molecular weight complexes in the cortex and hippocampus, as assessed by both N-terminal and C-terminal specific antibodies. The formation and release of CB1 oligomers was dramatically increased into CSF within 1 hour following traumatic brain insult. Novel CB1 receptor-based, prognostic markers of traumatic brain injury and other forms of brain injury are disclosed. A method of repopulating damaged neural cells by proliferation of a subgroup of neural progenitor cells is described. Targeting CB1 receptors for therapeutic neuroprotection in TBI is also disclosed.
Type:
Grant
Filed:
April 20, 2007
Date of Patent:
November 3, 2009
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Stanislav Svetlov, Ronald L. Hayes, Ka-Wang (Kevin) Wang
Abstract: The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.
Type:
Grant
Filed:
November 19, 2004
Date of Patent:
October 6, 2009
Assignees:
Satoris, Inc., The Borad of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Department of Veterans Affairs
Abstract: A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.
Type:
Grant
Filed:
May 20, 2005
Date of Patent:
September 8, 2009
Assignee:
Duke University
Inventors:
Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinov, Tatiana D. Sotnikova, Ranga R. Krishnan, David A. Schwartz, Lauranell Burch, Redford B. Williams